HOME >> BIOLOGY >> NEWS
Knocking out survival protein could aid leukemia treatment

COLUMBUS , Ohio -- An effective way to fight leukemia might be to knock out a specific protein that protects cancer cells from dying, a new study shows.

The findings suggest that a drug that can block this "survival protein" might on its own be an effective therapy.

But such a drug used in combination with several existing drugs might also offer an effective one-two punch against drug-resistant forms of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). The two forms of cancer kill about 20,500 Americans yearly.

The survival protein is called Mcl1. It usually helps keep normal cells healthy and is involved in the development of the components of the immune system, but it can also help prolong survival of cancer cells.

Cells with an overabundance of the protein are also more resistant to anticancer drugs such as rituximab, which has revolutionized the treatment of certain chronic and acute leukemias.

The study by researchers at the Ohio State University Comprehensive Cancer Center is published online in the journal Clinical Cancer Research.

"Our findings demonstrate that Mcl1 may be an effective target for drugs directed against CLL and ALL," says principal investigator John C. Byrd, professor of internal medicine and director of the hematologic malignancies program at Ohio State's James Cancer Hospital and Solove Research Institute.

"These results give us a rationale for lowering the amount of this protein in CLL cells and suggest that this should enhance the action of rituximab and perhaps other agents as well."

Rituximab is an antibody-based drug that targets CLL and ALL cells and causes the cells to self-destruct.

"We've shown that knocking down Mcl1 can, by itself, cause CLL cells to die, and that this effect might enhance the activity of rituximab," says first author Rehan Hussain, a postdoctoral fellow with Ohio State's Comprehensive Ca
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
20-Apr-2007


Page: 1 2

Related biology news :

1. New use for a cell toxin found to inhibit survival proteins in cancer cells
2. Glimmer of hope for Tahitian tree snails survival
3. Nexavar significantly extends overall survival by 44 percent in liver cancer patients
4. For many insects, winter survival is in the genes
5. HIV survival improves if patients stay in care
6. Preterm infants with RDS -- surfactant replacement therapies improves neonatal survival
7. Pancreatic cancer markers identified, may predict survival
8. Salk scientists hammer out a pathway that promotes muscle cell survival in mice
9. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer
10. Cetuximab increases survival in advanced colorectal cancer patients, study shows
11. Experience affects new neuron survival in adult brain; study sheds light on learning, memory

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Knocking out survival protein could aid leukemia treatment

(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
(Date:5/27/2015)... , May 26, 2015 Research ... of the "Global Breast Cancer Monoclonal Antibodies ... Globally, Roche seems to dominate the ... inventory. Its block buster molecule, Herceptin has been ... It was found that breast cancer cells become ...
(Date:5/27/2015)... Fla. (PRWEB) May 27, 2015 Expanding ... dental cement manufacturer Avalon Biomed Inc. recently ... of Mokuda Dental Co. Ltd. , the largest ... inroad into the international market for Avalon Biomed, which ... Plus®, award-winning tricalcium silicate-based dental cements that have won ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... MB (PRWEB) May 27, 2015 ... data to combat disease, Cubresa Inc. today announced ... “Our MR Compatible in-bore PET Scanner uses silicon ... into single-purpose preclinical MRI machines from manufacturers like ... Cubresa, headquartered in Winnipeg, Canada. “This enables simultaneous ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2
Cached News: